ELVBy Calypso Research6 min read

Elevance (ELV) Q4 2025 Earnings Analysis

Elevance Rises 5.9% Amid Medicaid Margin Madness

Key Takeaways

Elevance (ELV) reported Q4 2025 earnings with revenue of $49.7B, representing a +9.5% year-over-year change. The stock moved +5.9% on earnings day.

The bull case: Disciplined portfolio repositioning across all business lines sets up long-term sustainable margin growth. Confidence in at least 12% adjusted EPS growth coming off of our '26 ending baseline, with a strong external growth pipeline and positioning for sustainable business in ACA.

The bear case: Continued headwinds in Medicaid rates, Medicare Advantage funding, and membership losses pressure near-term earnings. Cost pressures in Medicaid are expected to remain elevated, and the Medicare Advantage landscape presents challenges for benefit stability and affordability.

Financial Highlights

  • Revenue: $49.7B (+9.5% YoY)
  • Gross Profit: $11.7B (23.5% margin, -2.8% YoY)
  • Operating Income: $581M (1.2% margin, -0.9% YoY)
  • Net Income: $547M
  • TTM Revenue: $199.1B

Stock Performance

  • Earnings Day Move: +5.9%
  • Year-to-Date: -5.2%
  • 1-Year Return: -12.8%
  • vs. S&P 500 (since earnings): +3.9%
  • vs. Nasdaq (since earnings): +5.0%

View live ELV data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from Elevance's Q4 2025 earnings call:

Sentiment: Negative

"In Medicaid, we expect cost pressure to remain pressured again in 2026 at roughly twice the historical average... cost trend here moving into that mid-single-digit range." — Mark Kaye
"The rate discussions today are increasingly tied to broader program changes and benefit designs... as we think about trying to maintain long-term sustainability." — Felicia Norwood

Medicare Advantage Membership Declines and Margin Outlook

Sentiment: Mixed

"Higher membership losses, but very consistent with the expectations... Importantly, we're positioned to deliver meaningful Medicare margin improvement to at least 2% in 2026." — Felicia Norwood
"We came into this... we believe we have improved our margin and, again, our sustainability." — Gail Boudreaux

CarillonRx and Carillon Services Growth vs. Membership Headwinds

Sentiment: Positive

"Our external growth pipeline is strong... if you take out that internal membership headwind, our overall growth would have been... high teens, low twenties for services." — Peter Haytaian
"We’re looking at serving the more complex populations based on the experience we have in our own health plans." — Gail Boudreaux

Commercial Membership Declines and Pricing Discipline

Sentiment: Mixed

"Employer group risk membership reflects our focus on margin stability... lower or negative margin public sector business that we had." — Mark Kaye
"We had about 11 bids in the second blue category for 2026. Won nine of them... the pipeline for 2027 looks strong." — Morgan Kendrick

Long-Term EPS Growth Confidence Despite Short-Term Challenges

Sentiment: Positive

"Looking to '27, we have confidence in at least 12% adjusted EPS growth coming off of our '26 ending baseline... pricing has hardened, and our operating decisions are designed to protect our earnings base." — Gail Boudreaux
"The path isn't predicated on a single assumption... it's built on multiple independent levers across commercial, Medicare, Carillon, and Medicaid." — Mark Kaye

Bull Case

Disciplined portfolio repositioning across all business lines sets up long-term sustainable margin growth. Confidence in at least 12% adjusted EPS growth coming off of our '26 ending baseline, with a strong external growth pipeline and positioning for sustainable business in ACA.

Bear Case

Continued headwinds in Medicaid rates, Medicare Advantage funding, and membership losses pressure near-term earnings. Cost pressures in Medicaid are expected to remain elevated, and the Medicare Advantage landscape presents challenges for benefit stability and affordability.

Looking Ahead

Investors will be closely watching Elevance's next quarterly report for continued execution, particularly around medicaid Margins and Rate Alignment Amid Elevated Cost Trends. With operating margins at 1.2%, margin trends will remain a focal point. The market's positive reaction on earnings day suggests confidence in management's direction, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was Elevance's revenue in Q4 2025?

Elevance reported Q4 2025 revenue of $49.7B, representing a +9.5% year-over-year change.

Did Elevance beat earnings expectations in Q4 2025?

The stock rose +5.9% on earnings day, suggesting the results met or exceeded market expectations. The current bull case centers on: Disciplined portfolio repositioning across all business lines sets up long-term sustainable margin growth. Confidence in at least 12% adjusted EPS growth coming off of our '26 ending baseline, with a strong external growth pipeline and positioning for sustainable business in ACA.

What is the bull case for ELV stock?

The bull case for ELV centers on: Disciplined portfolio repositioning across all business lines sets up long-term sustainable margin growth. Confidence in at least 12% adjusted EPS growth coming off of our '26 ending baseline, with a strong external growth pipeline and positioning for sustainable business in ACA.

What is the bear case for ELV stock?

The bear case for ELV centers on: Continued headwinds in Medicaid rates, Medicare Advantage funding, and membership losses pressure near-term earnings. Cost pressures in Medicaid are expected to remain elevated, and the Medicare Advantage landscape presents challenges for benefit stability and affordability.

How has ELV stock performed since its Q4 2025 earnings?

ELV moved +5.9% on the day of its Q4 2025 earnings report, outperforming the S&P 500 by +3.9% since earnings. Year-to-date, the stock has returned -5.2%.

View all Automotive Earnings Reports →

Browse all 400+ earnings reports →

Learn More

Analyze ELV in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for Elevance and 400+ other stocks, explore the full platform.

Open ELV on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.